Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akili, Inc.AKLI · Entity 89130 | Former Director and 10% Owner | August 19, 2022 | August 23, 2022 |
| Benitec Biopharma Inc.BNTC · Entity 5596 | 10% owner | December 23, 2025 | December 30, 2025 |
| Social Capital Suvretta Holdings Corp. IIDNAB · Entity 125597 | 10% owner | August 16, 2021 | August 16, 2021 |
| Social Capital Suvretta Holdings Corp. IVDNAD · Entity 123913 | 10% owner | August 16, 2021 | August 16, 2021 |
| Veradermics, IncMANE · Entity 1907 | See footnotes | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akili, Inc.
Report date August 19, 2022 · Filed August 23, 2022
Jointly reported with SCS Sponsor I LLC, Mehta Kishan, ChaChaCha DNA I, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,860,000 |
Reported balance
After 2022-08-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-08-19 · Exercise / conversion · Acquired 6,220,000 · Balance 6,860,000 F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-08-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-08-19 · Other · Disposed 6,860,000 · Balance 0 F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests. |
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-08-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-19 · Exercise / conversion · Disposed 6,220,000 · Balance 0 F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination. F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination"). F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B ordinary shares, par value $0.0001 per share (each a "Class B ordinary share"), held by the reporting owner, SCS Sponsor I LLC (the "Sponsor"), converted to the Issuer's common stock, par value $0.0001 per share ("Common Stock"), on a one-for-one basis upon the consummation of the business combination between the Issuer and Akili Interactive Labs, Inc. (the "Business Combination").
F2: The Sponsor is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by SC SPAC Holdings LLC, the successor by merger to ChaChaCha DNA I, LLC ("SC SPAC Holdings"). Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Mehta and Cowen and SC SPAC Holdings may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be.
F3: Represents the distribution for no consideration by the Sponsor of 6,860,000 shares of Common Stock to its members pro rata in accordance with their respective interests.
F4: The Class B ordinary shares converted to Common Stock on a one-for-one basis upon the consummation of the Business Combination.
Benitec Biopharma Inc.
Report date December 23, 2025 · Filed December 30, 2025
Jointly reported with MONTANOVA CAPITAL, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,620,075 |
Reported balance
After 2025-12-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-12-23 · Purchase · Acquired 42,600 · Balance 9,620,075 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,834,053 |
Reported balance
After 2025-12-23 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2025-12-23 · Purchase · Acquired 7,400 · Balance 1,834,053 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,634,395 |
Reported balance
After 2025-12-26 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2025-12-26 · Purchase · Acquired 14,320 · Balance 9,634,395 F4: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,836,569 |
Reported balance
After 2025-12-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2025-12-26 · Purchase · Acquired 2,516 · Balance 1,836,569 F5: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 9,700,195 |
Reported balance
After 2025-12-29 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2025-12-29 · Purchase · Acquired 65,800 · Balance 9,700,195 F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.0001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 1,848,156 |
Reported balance
After 2025-12-29 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2025-12-29 · Purchase · Acquired 11,587 · Balance 1,848,156 F7: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: Notes are included on Exhibit 99.1.
F2: Notes are included on Exhibit 99.1.
F3: Notes are included on Exhibit 99.1.
F4: Notes are included on Exhibit 99.1.
F5: Notes are included on Exhibit 99.1.
F6: Notes are included on Exhibit 99.1.
F7: Notes are included on Exhibit 99.1.
Social Capital Suvretta Holdings Corp. II
Report date August 16, 2021 · Filed August 16, 2021
Jointly reported with SCS Sponsor II LLC, Palihapitiya Chamath, Mehta Kishan, ChaChaCha DNA II, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 6,220,000 |
Reported balance
After 2021-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256724) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
F2: On August 16, 2021, SCS Sponsor II LLC forfeited at no cost 75,000 shares of Class B ordinary shares of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.
F3: The reporting owner, SCS Sponsor II LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA II, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.
Social Capital Suvretta Holdings Corp. IV
Report date August 16, 2021 · Filed August 16, 2021
Jointly reported with SCS Sponsor IV LLC, Palihapitiya Chamath, Mehta Kishan, ChaChaCha DNA IV, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B ordinary sharesSEC Table II · derivative / convertible security | Direct | 6,220,000 |
Reported balance
After 2021-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-16 · Disposition to issuer · Disposed 75,000 · Balance 6,220,000 F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date. F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares. F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the issuer's registration statement on Form S-1 (File No. 333-256727) under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer will automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of the issuer's initial business combination, or earlier at the option of the holder, on a one-for-one basis, subject to certain adjustment, and have no expiration date.
F2: On August 16, 2021, SCS Sponsor IV LLC forfeited at no cost 75,000 shares of Class B common stock of the issuer in connection with the election by the underwriters of the issuer's initial public offering to decline to exercise in full their option to purchase additional Class A ordinary shares.
F3: The reporting owner, SCS Sponsor IV LLC (the "Sponsor"), in whose name the securities reported herein are held, is managed by its managers, Chamath Palihapitiya and Kishan Mehta. A majority of the voting interests of the Sponsor are held by ChaChaCha DNA IV, LLC ("ChaChaCha"), which is controlled by Mr. Palihapitiya. Messrs. Mehta and Cowen may be deemed to control the other member of the Sponsor. Messrs. Palihapitiya, Mehta and Cowen and ChaChaCha may be deemed to beneficially own shares held by the Sponsor by virtue of their direct or indirect interests in the Sponsor or their shared control over the Sponsor, as the case may be. Each of Mr. Palihapitiya, Mr. Mehta, ChaChaCha and Mr. Cowen disclaims beneficial ownership of the shares held by the Sponsor, except to the extent of such person's pecuniary interest therein.
Veradermics, Inc
Report date August 19, 2026 · Filed August 21, 2026
Jointly reported with MONTANOVA CAPITAL, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 2,957,937 |
Reported balance
After 2026-08-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 690,601 · Balance 2,957,937 F2: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 461,033 |
Reported balance
After 2026-08-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2026-08-19 · Sale · Disposed 59,399 · Balance 461,033 F3: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 3,106,937 |
Reported balance
After 2026-08-20 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2026-08-20 · Other · Acquired 149,000 · Balance 3,106,937 F4: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Common stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectSee footnotes | 612,033 |
Reported balance
After 2026-08-20 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2026-08-20 · Other · Acquired 151,000 · Balance 612,033 F5: Notes are included on Exhibit 99.1. F6: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-20 · Other · Disposed 149,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F4: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
| Pre-Funded WarrantsSEC Table II · derivative / convertible security | IndirectSee footnotes | 0 |
Reported balance
After 2026-08-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-20 · Other · Disposed 151,000 · Balance 0 F6: Notes are included on Exhibit 99.1. F5: Notes are included on Exhibit 99.1. F7: Notes are included on Exhibit 99.1. F8: Notes are included on Exhibit 99.1. F1: Notes are included on Exhibit 99.1. |
Filing footnotes · ownership attribution and instrument terms
F1: Notes are included on Exhibit 99.1.
F2: Notes are included on Exhibit 99.1.
F3: Notes are included on Exhibit 99.1.
F4: Notes are included on Exhibit 99.1.
F5: Notes are included on Exhibit 99.1.
F6: Notes are included on Exhibit 99.1.
F7: Notes are included on Exhibit 99.1.
F8: Notes are included on Exhibit 99.1.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PROKIDNEY CORP.
Report date July 11, 2025 · Filed July 11, 2025
Section 16 reporting ended · disclosed 2025-07-11. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | OtherPre-Funded Warrants · Derivative | 151,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · derivative · entry 6 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 151,000 shares Expires not disclosed F6 · derivative.exercise_price: Notes are included on Exhibit 99.1. F5 · shares: Notes are included on Exhibit 99.1. F7 · derivative.exercise_date: Notes are included on Exhibit 99.1. F8 · derivative.exercise_date: Notes are included on Exhibit 99.1. F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F7 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | OtherPre-Funded Warrants · Derivative | 149,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · derivative · entry 5 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 149,000 shares Expires not disclosed F6 · derivative.exercise_price: Notes are included on Exhibit 99.1. F4 · shares: Notes are included on Exhibit 99.1. F7 · derivative.exercise_date: Notes are included on Exhibit 99.1. F8 · derivative.exercise_date: Notes are included on Exhibit 99.1. F7 · derivative.expiration_date: Notes are included on Exhibit 99.1. F7 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | OtherCommon stock, par value $0.00001 per share | 151,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · nonDerivative · entry 4 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 612,033 F5 · shares: Notes are included on Exhibit 99.1. F6 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| August 20, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | OtherCommon stock, par value $0.00001 per share | 149,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · nonDerivative · entry 3 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,106,937 F4 · shares: Notes are included on Exhibit 99.1. F6 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon stock, par value $0.00001 per share | 59,399 | $107.25 | $6,370,542.75 |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · nonDerivative · entry 2 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 461,033 F3 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| August 19, 2026 Filed Aug 21, 2026 22:11 UTC | Veradermics, Inc MANE · Entity 1907 | SaleCommon stock, par value $0.00001 per share | 690,601 | $107.25 | $74,066,957.25 |
DisclosureSEC source: 0000899140-26-000947 · form4.xml · nonDerivative · entry 1 MONTANOVA CAPITAL, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 2,957,937 F2 · shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:37 UTC | Veradermics, Inc MANE · Entity 1907 | GrantPre-Funded Warrants · Derivative | 151,000 | $100.00 | $15,099,984.90 |
DisclosureSEC source: 0000899140-26-000415 · form4.xml · derivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 151,000 Underlying: Common stock · 151,000 shares Expires not disclosed F4 · derivative.exercise_price: Notes are included on Exhibit 99.1. F3 · shares: Notes are included on Exhibit 99.1. F5 · derivative.exercise_date: Notes are included on Exhibit 99.1. F6 · derivative.exercise_date: Notes are included on Exhibit 99.1. F5 · derivative.expiration_date: Notes are included on Exhibit 99.1. F5 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| May 01, 2026 Filed May 6, 2026 01:37 UTC | Veradermics, Inc MANE · Entity 1907 | GrantPre-Funded Warrants · Derivative | 149,000 | $100.00 | $14,899,985.10 |
DisclosureSEC source: 0000899140-26-000415 · form4.xml · derivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director Cowen Aaron · CIK 0001869640 · See footnotes Averill Master Fund, Ltd. · CIK 0001939329 · Director Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 149,000 Underlying: Common stock · 149,000 shares Expires not disclosed F4 · derivative.exercise_price: Notes are included on Exhibit 99.1. F2 · shares: Notes are included on Exhibit 99.1. F5 · derivative.exercise_date: Notes are included on Exhibit 99.1. F6 · derivative.exercise_date: Notes are included on Exhibit 99.1. F5 · derivative.expiration_date: Notes are included on Exhibit 99.1. F5 · derivative.underlying_shares: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 19,338 | $36.55 | $706,803.90 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 19 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 520,453 F20 · shares: Notes are included on Exhibit 99.1. F20 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F20 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 06, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 11,183 | $35.97 | $402,252.51 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 18 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 501,115 F19 · shares: Notes are included on Exhibit 99.1. F19 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F19 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 16,563 | $39.80 | $659,207.40 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 17 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 489,932 F18 · shares: Notes are included on Exhibit 99.1. F18 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F18 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 17,835 | $38.67 | $689,679.45 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 16 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 473,369 F17 · shares: Notes are included on Exhibit 99.1. F17 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F17 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 38,771 | $37.63 | $1,458,952.73 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 15 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 455,534 F16 · shares: Notes are included on Exhibit 99.1. F16 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F16 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 19,199 | $36.93 | $709,019.07 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 14 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 416,763 F15 · shares: Notes are included on Exhibit 99.1. F15 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F15 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 3,832 | $36.07 | $138,220.24 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 13 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 397,564 F14 · shares: Notes are included on Exhibit 99.1. F14 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F14 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 3,178 | $38.90 | $123,624.20 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 12 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 393,732 F13 · shares: Notes are included on Exhibit 99.1. F13 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F13 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 4,453 | $38.09 | $169,614.77 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 11 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 390,554 F12 · shares: Notes are included on Exhibit 99.1. F12 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F12 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 9,168 | $37.11 | $340,224.48 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 10 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 386,101 F11 · shares: Notes are included on Exhibit 99.1. F11 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F11 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 2,519 | $36.27 | $91,364.13 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 9 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 376,933 F10 · shares: Notes are included on Exhibit 99.1. F10 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F10 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 1,835 | $34.74 | $63,747.90 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 8 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 374,414 F9 · shares: Notes are included on Exhibit 99.1. F9 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F9 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 1,720 | $34.25 | $58,910.00 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 7 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 372,579 F8 · shares: Notes are included on Exhibit 99.1. F8 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F8 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 18,489 | $38.90 | $719,222.10 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 6 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,648,538 F7 · shares: Notes are included on Exhibit 99.1. F7 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F7 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 25,908 | $38.09 | $986,835.72 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 5 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,630,049 F6 · shares: Notes are included on Exhibit 99.1. F6 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 53,344 | $37.11 | $1,979,595.84 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,604,141 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 14,659 | $36.27 | $531,681.93 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,550,797 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 10,676 | $34.74 | $370,884.24 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,536,138 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| February 04, 2026 Filed Feb 9, 2026 23:28 UTC | Veradermics, Inc MANE · Entity 1907 | PurchaseCommon stock, par value $0.00001 per share | 10,004 | $34.25 | $342,637.00 |
DisclosureSEC source: 0000899140-26-000140 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 3,525,462 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 11,587 | $13.44 | $155,729.28 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 6 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,848,156 F7 · shares: Notes are included on Exhibit 99.1. F7 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F7 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 29, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 65,800 | $13.44 | $884,352.00 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 5 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,700,195 F6 · shares: Notes are included on Exhibit 99.1. F6 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 2,516 | $13.10 | $32,959.60 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,836,569 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 26, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 14,320 | $13.10 | $187,592.00 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,634,395 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 7,400 | $12.85 | $95,090.00 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,834,053 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 23, 2025 Filed Dec 30, 2025 00:31 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 42,600 | $12.85 | $547,410.00 |
DisclosureSEC source: 0000899140-25-001479 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,620,075 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 2,892 | $12.08 | $34,935.36 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 6 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,826,653 F7 · shares: Notes are included on Exhibit 99.1. F7 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F7 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 22, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 16,650 | $12.08 | $201,132.00 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 5 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,577,475 F6 · shares: Notes are included on Exhibit 99.1. F6 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F6 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 2,434 | $11.48 | $27,942.32 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,823,761 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 19, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 13,950 | $11.48 | $160,146.00 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,560,825 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 1,515 | $11.24 | $17,028.60 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,821,327 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 18, 2025 Filed Dec 23, 2025 00:45 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 8,700 | $11.24 | $97,788.00 |
DisclosureSEC source: 0000899140-25-001459 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,546,875 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 02:51 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 751,111 | $13.50 | $10,139,998.50 |
DisclosureSEC source: 0000899140-25-001256 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,819,812 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 02:51 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 730,370 | $13.50 | $9,859,995.00 |
DisclosureSEC source: 0000899140-25-001256 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 9,538,175 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:37 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 670 | $13.22 | $8,857.40 |
DisclosureSEC source: 0000899140-25-000486 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,068,701 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:37 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 5,057 | $13.22 | $66,853.54 |
DisclosureSEC source: 0000899140-25-000486 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,807,805 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:37 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 1,267 | $12.63 | $16,002.21 |
DisclosureSEC source: 0000899140-25-000486 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,068,031 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:37 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 9,503 | $12.63 | $120,022.89 |
DisclosureSEC source: 0000899140-25-000486 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,802,748 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:51 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 106,200 | $13.00 | $1,380,600.00 |
DisclosureSEC source: 0000899140-25-000479 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,066,764 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 20:51 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 793,800 | $13.00 | $10,319,400.00 |
DisclosureSEC source: 0000899140-25-000479 · form4.xml · nonDerivative · entry 1 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 8,793,245 F2 · shares: Notes are included on Exhibit 99.1. F2 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F2 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 21:28 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 2,288 | $11.25 | $25,740.00 |
DisclosureSEC source: 0000899140-24-001385 · form4.xml · nonDerivative · entry 4 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 960,554 F5 · shares: Notes are included on Exhibit 99.1. F5 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F5 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 24, 2024 Filed Dec 26, 2024 21:28 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 17,730 | $11.25 | $199,462.50 |
DisclosureSEC source: 0000899140-24-001385 · form4.xml · nonDerivative · entry 3 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 7,999,455 F4 · shares: Notes are included on Exhibit 99.1. F4 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F4 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
| December 23, 2024 Filed Dec 26, 2024 21:28 UTC | Benitec Biopharma Inc. BNTC · Entity 5596 | PurchaseCommon stock, par value $0.0001 per share | 3,142 | $10.98 | $34,499.16 |
DisclosureSEC source: 0000899140-24-001385 · form4.xml · nonDerivative · entry 2 SUVRETTA CAPITAL MANAGEMENT, LLC · CIK 0001569064 · Director · 10% owner Averill Madison Master Fund, Ltd. · CIK 0002021243 · Director · 10% owner Averill Master Fund, Ltd. · CIK 0001939329 · Director · 10% owner Cowen Aaron · CIK 0001869640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 958,266 F3 · shares: Notes are included on Exhibit 99.1. F3 · price: Notes are included on Exhibit 99.1. F1 · ownership.direct: Notes are included on Exhibit 99.1. F1 · ownership.nature: Notes are included on Exhibit 99.1. F3 · ownership.nature: Notes are included on Exhibit 99.1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.